Sun Pharma’s June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative medicines portfolio significantly. Strategic initiatives like semaglutide launches and the Organon acquisition are key drivers. Despite US generics pressure, domestic business and specialty products show strong momentum. Analysts maintain a positive outlook, anticipating substantial growth from these ventures.
Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
Laurus Labs shares rose 3.79% to Rs 2,329 after the pharmaceutical company reported strong Q2FY27 results. Revenue increased 33% year-on-year to Rs 2,206 crore, while
October 30, 2026